161 related articles for article (PubMed ID: 9117144)
1. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points.
Kinlay S; Selwyn AP; Delagrange D; Creager MA; Libby P; Ganz P
Curr Opin Lipidol; 1996 Dec; 7(6):389-97. PubMed ID: 9117144
[TBL] [Abstract][Full Text] [Related]
2. [The promise of statins].
Capurso A
Ital Heart J Suppl; 2001 Mar; 2(3):224-9. PubMed ID: 11307780
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol lowering and the vessel wall: new insights and future perspectives.
Stulc T; Ceska R
Physiol Res; 2001; 50(5):461-71. PubMed ID: 11702850
[TBL] [Abstract][Full Text] [Related]
4. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?
Cohen JD; Drury JH; Ostdiek J; Finn J; Babu BR; Flaker G; Belew K; Donohue T; Labovitz A
Am Heart J; 2000 Apr; 139(4):734-8. PubMed ID: 10740160
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of atherosclerotic plaque during lipid lowering.
Müller-Wieland D; Kotzka J; Krone W
Curr Opin Lipidol; 1997 Dec; 8(6):348-53. PubMed ID: 9412775
[TBL] [Abstract][Full Text] [Related]
6. Role of endothelial dysfunction in coronary artery disease and implications for therapy.
Kinlay S; Ganz P
Am J Cardiol; 1997 Nov; 80(9A):11I-16I. PubMed ID: 9375937
[TBL] [Abstract][Full Text] [Related]
7. Endothelial dysfunction and dyslipidemia: possible effects of lipid lowering and lipid modifying therapy.
van Boven AJ; Jukema JW; Paoletti R
Pharmacol Res; 1994 Apr; 29(3):261-72. PubMed ID: 8058597
[TBL] [Abstract][Full Text] [Related]
8. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention.
Fathi R; Haluska B; Short L; Marwick TH
Am J Med; 2003 Apr; 114(6):445-53. PubMed ID: 12727577
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of plaque stabilization].
Müller-Wieland D; Faust M; Kotzka J; Krone W
Herz; 1999 Feb; 24(1):26-31. PubMed ID: 10093010
[TBL] [Abstract][Full Text] [Related]
11. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease.
Selwyn AP; Kinlay S; Libby P; Ganz P
Circulation; 1997 Jan; 95(1):5-7. PubMed ID: 8994406
[TBL] [Abstract][Full Text] [Related]
12. Effect of lipid-lowering therapy on vasomotion and endothelial function.
Kinlay S; Plutzky J
Curr Cardiol Rep; 1999 Sep; 1(3):238-43. PubMed ID: 10980848
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis.
Ganz P; Creager MA; Fang JC; McConnell MV; Lee RT; Libby P; Selwyn AP
Am J Med; 1996 Oct; 101(4A):4A10S-16S. PubMed ID: 8900332
[TBL] [Abstract][Full Text] [Related]
14. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
15. Effect of lipid-lowering therapy on myocardial ischemia.
Tzivoni D; Klein J
Cardiovasc Drugs Ther; 1998 Apr; 12 Suppl 1():135-9. PubMed ID: 9642487
[TBL] [Abstract][Full Text] [Related]
16. What have we learned about the biology of atherosclerosis? The role of inflammation.
Libby P
Am J Cardiol; 2001 Oct; 88(7B):3J-6J. PubMed ID: 11595192
[TBL] [Abstract][Full Text] [Related]
17. [Prevention and therapy of vascular damage and endothelial dysfunction with hypocholesteremic agents].
De Caterina R; Lenzi S
G Ital Cardiol; 1998 Feb; 28(2):168-77. PubMed ID: 9534058
[TBL] [Abstract][Full Text] [Related]
18. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
Anderson TJ; Meredith IT; Yeung AC; Frei B; Selwyn AP; Ganz P
N Engl J Med; 1995 Feb; 332(8):488-93. PubMed ID: 7830729
[TBL] [Abstract][Full Text] [Related]
19. New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease.
Gould KL
Am J Med; 1998 Jun; 104(6A):2S-17S. PubMed ID: 9684847
[TBL] [Abstract][Full Text] [Related]
20. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
